StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63−0.05 (-7.21%)

Close on Nov 17, 2026Market cap $23.84MP/E –Yield –

Metagenomi Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Metagenomi Therapeutics's price to book ratio was 0.3× on Nov 11, 2026, against 0.4× a year earlier. Over the last 3 years it ranged from 0.2× to 0.9×, with a median of 0.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.3×−0.1
2025Dec 31, 20250.3×−0.2
2024Dec 31, 20240.5×–

More Metagenomi Therapeutics figures

See a number that looks wrong?